Zuleski F R, Kirkland K M, Melgar M D, Malbica J O
Drug Metab Dispos. 1985 Mar-Apr;13(2):139-47.
Tracazolate (4-n-butylamino-1-ethyl-6-methyl-1H-pyrazolo[3,4-b] pyridine-5-carboxylic acid ethyl ester) undergoes extensive biotransformation to lipophilic metabolites following oral dosage to male rats. Twenty-one metabolites were identified in a plasma hexane extract by mass spectrometry. Coadministration of unlabeled tracazolate with its stable carbon-13 isotope expedited the isolation and identification of 11 biotransformation products. The various metabolites resulted from either hydrolysis, oxidation, dealkylation, or conversion of an ethyl group to a vinyl group and also from combinations of these biotransformation reactions. Brain extract contained tracazolate and 12 of the metabolites found in plasma. Extracts of fat contained tracazolate and nine of the plasma metabolites. An uncommon type of metabolite less polar than tracazolate (1-vinyl tracazolate) was isolated by HPLC and identified by mass spectrometry.
曲卡唑酯(4-正丁基氨基-1-乙基-6-甲基-1H-吡唑并[3,4-b]吡啶-5-羧酸乙酯)经口服给予雄性大鼠后会广泛生物转化为亲脂性代谢物。通过质谱法在血浆己烷提取物中鉴定出21种代谢物。未标记的曲卡唑酯与其稳定的碳-13同位素共同给药加快了11种生物转化产物的分离和鉴定。各种代谢物是由水解、氧化、脱烷基化、乙基转化为乙烯基反应产生的,也可由这些生物转化反应的组合产生。脑提取物中含有曲卡唑酯和血浆中发现的12种代谢物。脂肪提取物中含有曲卡唑酯和9种血浆代谢物。通过高效液相色谱法分离出一种比曲卡唑酯极性小的罕见代谢物类型(1-乙烯基曲卡唑酯),并通过质谱法进行了鉴定。